We are happy to report on the acceptance of Tamas Sohajda‘s new patent on the use of single isomer chemically modified cyclodextrin for treating lysosomal storage diseases. Sugammadex and similar compounds are mentioned as potential active ingredients in this patent.
Our group has always been fond of photodynamic therapy, and here is a great example of why: β-galactosidase activated PDT for selective imaging and targeted treatment of glioblastoma delivered by Orta Doğu Teknik Üniversitesi / Middle East Technical University and Koç University Gorkem Gunbas Toghrul Almammadov Safacan Kölemen
Full article: https://pubs.acs.org/doi/10.1021/acsabm.2c00484
Automated solution-phase multiplicative synthesis of complex glycans enabled by preactivation-based, multi-component, one-pot glycosylation and continuous multiplying amplification published by Peking University. Wonderful!
A little business for today:
ZyVersa Therapeutics Inc., a clinical-stage specialty biopharmaceutical company developing, among others, a cyclodextrin drug candidate (VAR 200), announced an aggregate committed financing in support of the business combination at $10.0 million.
This investment will enable Zyversa to advance clinical evaluation of the cholesterol efflux mediator candidate (VAR 200) in patients with orphan renal disease, FSGS, and to progress into Phase 1 trials – said Steve Glover and Daniel J. O’Connor
Read more on the ZyVersa website
Bathing in carbs: Lai-Xi Wang and his group from the University of Maryland reported the synthesis of cyclodextrin-based multivalent glycan ligands for human galectin-3. The GalNAc (Tn antigen) containing heptavalent ligand showed the highest affinity for human Gal-3 among the synthetic ligands tested, with an EC50 of 1.4 μM in binding to human Gal-3.
Great read on pore-forming lectin SaroL-1 punching holes in cancer cells by targeting the tumor-related glycosphingolipid Gb3 presented by a well-known team led by Anne Imberty (Grenoble University), Winfried Römer (Université de Fribourg – Universität Freiburg) and Frederique Lisacek (University of Geneva)
Fascinating!
Great paper on the relations of Gal-3 levels and Aβ deposits and tau aggregates in #brain tissue in #alzheimersdisease published by a great collaboration of the University of Seville, ENS-PSL, EHESS, Université Paris Cité, Lund University, and the University of Gothenburg.
#neurodegenerativediseases #alzheimers #brainhealth #carbohydrates #glycotime
Cyclodextrin derivatives were demonstrated to be endowed with intrinsic antiviral action against several viruses (herpes, HIV, RSV, influenza, covid19, etc.). In this great work from Rachele Francese, Francesco Trotta, Claudio Cecone, Matteo Constantino, Gjylije Hoti, Pierangiola Bracco, and David Lembo from the University of Turin, four water-soluble hyper-branched beta cyclodextrin anionic polymer were screened against herpes simplex virus (HSV-2), respiratory syncytial virus (RSV), rotavirus (HRoV), and influenza virus (FluVA). The results suggest that the polymer virucidal activity against RSV can be exploited to produce new antiviral materials to counteract the virus dissemination through the air or direct contact.
This week seems to be all about cyclodextrin.
Chris Kevil’s group (Gopi Krishna Kolluru et al.) from Louisiana State University discovered the Sugammadex (among other prodrugs) could serve as an H2S donor and support the treatment of covid patients. Amazing work!
Great paper from The University of Kansas by Mark P. Farrell and their team on lectin drug conjugates targeting N-glycans.
Read more: https://chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/cbic.202200266
